A group of Democratic and Republican senators introduced a bill on Thursday that calls for $275 million toward federal menopause research and awareness efforts over five years. The legislation would ...
Sarepta Therapeutics’ chief scientist suggested that the FDA was ahead of schedule in reviewing the company’s application to ...
The Federal Trade Commission has extended its antitrust review of Novo Holdings’ $16.5 billion purchase of Catalent by potentially another 30 days as it requests additional information. Both the ...
Jang-Ho Cha had no interest in leaving his post at Novartis, where he led translational medicine for the pharma giant’s work ...
For biosimilars to win, AbbVie has to lose, according to Boehringer Ingelheim. The German drugmaker on Wednesday said that ...
Newly appointed CEO Joe Papa outlined his vision for Emergent BioSolutions, which includes winding down two facilities and ...
The Senate Finance Committee released a bipartisan draft legislation on Friday morning that would give Medicare bonuses to healthcare providers that help fight generic drug shortages. “It is ...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and ...
AstraZeneca is working on moving its BTK inhibitor Calquence into earlier stages of mantle cell lymphoma, releasing what it ...
GSK wants to present Blenrep to regulatory bodies sooner. The UK pharma will submit Blenrep in second-line multiple myeloma ...
Bristol Myers Squibb will give back a preclinical cancer drug to Schrödinger, returning the SOS1 inhibitor that was part of a ...
Moderna’s shift to a more “restrained” posture was on full display Thursday morning during its first-quarter earnings update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results